Methiopropamine

From PsychonautWiki
(Redirected from MPA)
Jump to navigation Jump to search
Summary sheet: Methiopropamine
Methiopropamine
Methiopropamine.svg
Chemical Nomenclature
Common names MPA
Substitutive name Methiopropamine
Systematic name 1-(Thiophen-2-yl)-2-methylaminopropane
Class Membership
Psychoactive class Stimulant
Chemical class Thiophene
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 10 mg
Light 20 - 30 mg
Common 30 - 50 mg
Strong 50 - 60 mg
Heavy 60 mg +
Duration
Total 6 - 10 hours
Onset 30 - 60 minutes
Peak 2 - 4 hours
Offset 2 - 3 hours
After effects 1 - 2 hours



Insufflated
Dosage
Threshold 5 mg
Light 5 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Duration
Total 2 - 4 hours
Onset 5 - 10 minutes
Come up 5 - 10 minutes
Peak 30 - 60 minutes
Offset 30 - 120 minutes
After effects 6 - 8 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
MXE
Dissociatives
DXM
MDMA
Stimulants
25x-NBOMe
25x-NBOH
Tramadol
MAOIs


Methiopropamine (also known as MPA) is a stimulant substance of the thiophene class. It is a ring-based structural analogue of methamphetamine.

Methiopropamine was first synthesized in 1942.[1] It appeared for public sale in the U.K. in December 2010 as a research chemical or legal high, recently branded as "Blow".[2]

Subjective effects are reportedly similar to those of classical stimulants and includes stimulation, focus enhancement, motivation enhancement, increased libido, appetite suppression, and euphoria. However, it is generally considered to be as euphoric or recreational as classical stimulants. It is occasionally reported to be used as a study aid.

Limited data exists about the pharmacology and toxicity of methiopropamine in humans, and it has only a short history of human use. It is highly advised to use harm reduction practices if using this substance.

Chemistry

Methiopropamine, or 1-(thiophen-2-yl)-2-methylaminopropane, is a synthetic molecule of the thiophene class. It is a structural analogue to methamphetamine. It contains a thiophene ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Methiopropamine contains an additional methyl substitution at RN (similarly to MDMA and methamphetamine). Although methiopropamine is analogous to methamphetamine, it is neither an amphetamine nor a phenethylamine as methiopropamine contains a thiophene ring instead of a benzene ring. Thiophene is a five-membered aromatic ring with a sulphur constituent.

Pharmacology

Methiopropamine functions as a selective norepinephrine-dopamine releasing agent. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects. It is approximately one third as potent as dextroamphetamine as a norepinephrine reuptake inhibitor and one fifth as much as a dopamine reuptake inhibitor. It displays negligible activity as a serotonin reuptake inhibitor.[3]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
Child.svg

Cognitive effects
User.svg

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational MPA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MPA has very little history of human usage. Anecdotal evidence from people who have tried MPA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

As with other stimulants, the chronic use of MPA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MPA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MPA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of MPA all stimulants will have a reduced effect.

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[4] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[4][5] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[4]

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

  • Austria: Since June 26, 2019, Methiopropamine is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)[8]
  • China: Methiopropamine is a controlled substance.[9]
  • Finland: Methiopropamine is illegal in Finland.[citation needed]
  • Germany: Methiopropamine is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[10] as of July 17, 2013.[11] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[12]
  • Switzerland: Methiopropamine is a controlled substance specifically named under Verzeichnis D.[13]
  • United Kingdom: Methiopropamine is a Class B drug.[14]
  • United States: Methiopropamine is not scheduled at the federal level in the United States,[15] but it could be considered an analogue of methamphetamine in which case purchase, sale, or possession could be prosecuted under the Federal Analogue Act. Methiopropamine's structure differs from methamphetamine's structure significantly more than previous successful prosecutions under the same law.[citation needed]
    • Florida: Methiopropamine is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess in Florida.[16]

See also

External links

References

  1. Blicke, F. F., Burckhalter, J. H. (March 1942). "α-Thienylaminoalkanes". Journal of the American Chemical Society. 64 (3): 477–480. doi:10.1021/ja01255a001. ISSN 0002-7863. 
  2. Angelov, D., O’Brien, J., Kavanagh, P. (March 2013). "The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards". Drug Testing and Analysis. 5 (3): 145–149. doi:10.1002/dta.298. ISSN 1942-7611. 
  3. Iversen, L., Gibbons, S., Treble, R., Setola, V., Huang, X.-P., Roth, B. L. (30 January 2013). "Neurochemical profiles of some novel psychoactive substances". European Journal of Pharmacology. 700 (1): 147–151. doi:10.1016/j.ejphar.2012.12.006. ISSN 0014-2999. 
  4. 4.0 4.1 4.2 Shoptaw, S. J., Kao, U., Ling, W. (21 January 2009). Cochrane Drugs and Alcohol Group, ed. "Treatment for amphetamine psychosis". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003026.pub3. ISSN 1465-1858. 
  5. Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects (2nd ed ed.). Oxford University Press. ISBN 9780195030563. 
  6. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  7. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  8. https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig
  9. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. Archived from the original on February 10, 2017. Retrieved December 28, 2019. 
  10. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019. 
  11. "Siebenundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 18, 2019. 
  12. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 18, 2019. 
  13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2017 
  15. http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm
  16. Statutes & Constitution :View Statutes : Online Sunshine